Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Swedish Orphan Biovitrum AB (publ)
Operating Income
Swedish Orphan Biovitrum AB (publ)
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Operating Income
kr5.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Operating Income
kr423.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Operating Income
kr166.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Operating Income
kr783m
|
CAGR 3-Years
23%
|
CAGR 5-Years
10%
|
CAGR 10-Years
19%
|
|
|
Probi AB
STO:PROB
|
Operating Income
kr3.1m
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-18%
|
|
|
BioArctic AB
STO:BIOA B
|
Operating Income
-kr228.5m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Swedish Orphan Biovitrum AB (publ)
Glance View
Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.
See Also
What is Swedish Orphan Biovitrum AB (publ)'s Operating Income?
Operating Income
5.8B
SEK
Based on the financial report for Dec 31, 2024, Swedish Orphan Biovitrum AB (publ)'s Operating Income amounts to 5.8B SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Operating Income growth rate?
Operating Income CAGR 5Y
5%
Over the last year, the Operating Income growth was 25%. The average annual Operating Income growth rates for Swedish Orphan Biovitrum AB (publ) have been 15% over the past three years , 5% over the past five years .
You don't have any saved screeners yet